Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

Exclusion Criteria

• •Pregnant or nursing (lactating) women
• •Stroke or myocardial infarction less than 3 months before Screening
• •Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline.
• •Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye
• •Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye
• •Neovascularization of the iris or neovascular glaucoma in the study eye
• •Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline
• •Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye
• •Focal or grid laser photocoagulation within 4 months before Baseline in the study eye
• •Use of intra- or periocular corticosteroids (including sub-Tenon) within 3 months before Screening in the study eye
• •Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye